SAN FRANCISCO--(BUSINESS WIRE)--
Twist Bioscience Corporation (TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it will issue its financial results for the fiscal 2019 first quarter ended December 31, 2018, following the close of market on Thursday, February 7, 2019. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “company” tab at www.twistbioscience.com.
The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 7382069. A telephonic replay of the conference call will be available beginning approximately four hours after the call through February 14, 2019, and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 7382069. The webcast replay will be available for two weeks.
About Twist Bioscience Corporation
Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.